This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dividend Increases, Research Nominations, New Treatment Options, And Clinical Trials - Research Report On Covidien, Ironwood, ICON, Novadaq, And Antares

NEW YORK, October 2, 2013 /PRNewswire/ --

Editor Note: For more information about this relea se, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Covidien plc (NYSE: COV), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), ICON plc (NASDAQ: ICLR), Novadaq Technologies Inc. (NASDAQ: NVDQ), and Antares Pharma Inc. (NASDAQ: ATRS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Covidien plc Research Report

On September 19, 2013, Covidien plc (Covidien) announced that its Board of Directors has authorized a 23% increase in its quarterly dividend rate. The revised dividend will be $0.32 per ordinary share compared to the previous $0.26 per ordinary share. "This increase reflects our good performance to date in 2013 and our confidence in further growth," said José E. Almeida, Chairman, President and CEO. "We remain committed to using our strong cash flow to fund business expansion, while returning at least 50% of our free cash flow to shareholders through dividends and share repurchases. In the last twelve months, we have exceeded this target, returning over 125% of our free cash flow to shareholders." The Company reported that quarterly dividend is payable on November 5, 2013, to shareholders of record as on October 10, 2013. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/a14c_COV]

--

Ironwood Pharmaceuticals Inc. Research Report

On September 10, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) and AstraZeneca Pharmaceuticals Co., Ltd. (AstraZeneca) announced the beginning of a Phase III clinical trial in China of linaclotide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). "IBS-C is estimated to affect at least 13 million adults in China, causing hallmark symptoms such as abdominal pain and constipation," said David Snow, President of AstraZeneca China. "If approved in China, linaclotide could be the first prescription treatment specifically for IBS-C and could then help address an unmet need for millions of suffering patients." Ironwood and AstraZeneca anticipate the availability of top-line data in H1 2015 and, if approved by the China Food and Drug Administration(CFDA), anticipate that linaclotide could be commercialized in China in 2017. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/dbc4_IRWD]

--

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs